NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Anika and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."

More on TelAve News

• Phinge Previews Its Magnetically Connectable 360° Folding Smartphones-to-Tablets As The Exclusive Gateway to Netverse App-less Rewards-based Platform
• BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
• IRL Investigations Combines Decades of Experience with Modern Digital Expertise
• New Leadership Model – Never Fire Anyone – Released Today
• AureaVault Launches U.S.-Licensed Cryptocurrency Exchange with Enhanced Security Features

On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

---

Show All News | Report Violation